FDA Authorizes Marketing of Device That Can Improve Gait in Multiple Sclerosis Patients

FDA is taking an initiative to authorize the marketing of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients which can help patients with their motor deficit to some extent.

Are you aware of the condition called Multiple Sclerosis? This is one of the leading causes of neurological disability in many patients worldwide. It basically affects the nerve lining sheath. When this nerve sheath gets worn out, it results in electric shock, and pain may affecting their functions like talking, walking, and writing. Just imagine, the outer covering of the nerve sheath gets worms out causing intense damage to the actual nerve. It can get really painful and affect your walking and speech as the communication between the brain and body is carried by nerves. In the end, the nervous system gets disrupted resulting in slow walking and delayed speech. As age advances, the person suffering from Multiple Sclerosis gets further deteriorated. 

FDA comes to help the patients with Multiple Sclerosis

On 26th March 2021, the Food and Drug Administration (FDA) authorized the marketing of a device that can help patients of Multiple Sclerosis with gait deficit with mild to moderate symptoms. The device is to be used by a prescription only as an adjunct to supervise exercise training programs in patients with Multiple Sclerosis at age 22 or older. The device is called Portable Neuromodulation Stimulator (PoNS) is a neuromuscular stimulator which helps generate electrical impulses or trigeminal and facial nerve via the tongue to provide treatment for motor deficit problems. 

What is Multiple Sclerosis?

Multiple sclerosis is a chronic disease of the central nervous system. It is an autoimmune disorder, a condition in which the body mistakenly attacks its own healthy cells. Multiple Sclerosis is an unpredictable disease that affects people differently. The symptoms may vary from patient to patient and each may depend upon the area of damage. Multiple Sclerosis is the second cause of neurological disease and disability, after trauma. It affects more men than women. 

The real science behind Multiple Sclerosis 

As the name suggests, there is sclerosis or degradation of the outer sheath of the nerve which is also known as the myelin sheath. Myelin sheath is the outer fatty layer of the nerve. This myelin sheath protects the nerve fibers by providing a shield to the actual nerve. In Multiple Sclerosis , the myelin sheath is destroyed in many years affecting their functioning. This loss of myelin forms scar tissue called sclerosis. When the nerves are damaged in this way, they conduct electrical impulses to and from the brain. 

Causes for Multiple Sclerosis 

Autoimmune causes  Infectious agents such as virus  Environmental factors  Genetic factors 

Symptoms of Multiple Sclerosis 

The symptoms of Multiple Sclerosis are unpredictable. They may be mild or severe, short-term or long-lasting. Theory may appear in different combinations, dispensing on the area of the nervous system affected. The following are the most common symptoms of Multiple Sclerosis. But each person may have different symptoms. 

Blurred or double vision Red or green color distortion  Pain or loss of vision because of swelling of the optic nerve  Trouble walking  An abnormal feeling such as numbness or pricking sensation of pins and needles Muscle weakness in arms and legs  Difficulty in coordination while walking and standing  Spasticity: Involuntary increased tone of muscles Stiffness Of muscles Spasm of muscles  Fatigue on physical activity  Constant tiredness that does not go away  Loss of feeling  Speech problems: delayed of slurred speech  Tremors  Dizziness  Hearing loss  Bowel and Bladder problem  Depression  Changes in sexual function  Thinking inability or cognitive function  Difficulty in focus and attention  Memory loss  Poor judgment 

All you need to know about the Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients 

The FDA assesses the safety and effectiveness of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients through 2 clinical studies and retrospective analysis of the Real-World Clinical Data (RWD). The FDA is granted marked authorization of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients to Helius Medical Inc. 

Tags : #myhealth #medicircle #FDA #multiplesclerosis #PortableNeuromodulationStimulator

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
Reducing Stigma, One Story at a Time: Media's Role in Mental HealthMay 07, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024